Levels of the GFAP protein in blood are significantly higher in Parkinson’s disease patients with cognitive impairment — particularly those with dementia — compared with healthy people, a new study shows. According to researchers, blood GFAP levels could accurately identify Parkinson’s patients with mild cognitive impairment (MCI) who ended…
A new device called Izar that aims to help assess and train hand function for people with neurological disorders such as Parkinson’s disease is now available in the U.S., as well as in European countries including France, Switzerland, and Germany. According to its manufacturer, MindMaze, the hand-sized device is…
Cerevance is planning to launch a Phase 2 clinical trial in the second quarter of this year to test its experimental oral medication CVN424 in people newly diagnosed with Parkinson’s disease. The company announced $51 million in new funding, from an expanded round of Series B Financing, for…
People with sporadic Parkinson’s disease and those with Parkinson’s-associated mutations in the GBA gene show a distinct immune cell profile in the blood relative to healthy people, a study showed. In turn, Parkinson’s patients carrying disease-causing LRRK2 mutations had an immune cell profile comparable to people without any disease.
People with Parkinson’s disease are more likely to report a good quality of life if their caregivers are not strained, a new study suggests. “As caregiver strain was found to be related to patients’ QoL [quality of life], improvement in QoL for PD [Parkinson’s disease] patients may hinge on…
Shirley Ryan AbilityLab, a rehabilitation center located in Chicago, Illinois, will conduct a study that will use Datos Health‘s remote care platform Open Care to monitor physical activity in people with Parkinson’s disease and other neurological disorders. “The research study will allow us to determine the feasibility…
Nervtex’s MoDAS artificial intelligence (AI) system has become the first video-based, AI-powered medical device to win regulatory approval for assessing motor symptoms in Parkinson’s disease and other movement disorders, according to a company press release. The AI system, which analyzes motor symptoms based on video recorded on a…
ATH434, Alterity Therapeutics’ experimental oral therapy, prevented a loss in the sense of smell — an early and common symptom of Parkinson’s disease — in a mouse model, and helped to preserve nerve cells and restore motor skills in older animals, a study showed. These findings add to those…
The activity of multiple genes in the brain varies according to sex among people with Parkinson’s disease, a new study reports. These differences may contribute to discrepancies in how Parkinson’s tends to affect men and women. “While males have a higher age-adjusted disease incidence and are more frequently affected…
Suppressing the production of an enzyme called nitric oxide synthase 2 (NOS2) led to reductions in alpha-synuclein-related abnormalities and neuroinflammation in a mouse model of Parkinson’s disease, a new study reports. “Our data indicate that NOS2 may be a therapeutic target for modulating [Parkinson’s disease] in the brain,” the…
Get regular updates to your inbox.
